A. Craig

发表

218 A phase I and pharmacokinetic trial ARQ 501, an Activated Checkpoint Therapy (TM) agent, in patients with advanced solid tumors

Suzanne F. Jones, G. Shapiro, D. Ryan, 2004 .

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Jennifer A. Smith, G. Acton, H. Kantarjian, 2018, Haematologica.

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

J. Nemunaitis, M. Mita, A. Mita, 2012, Cancer Chemotherapy and Pharmacology.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

M. Maris, F. Ravandi, J. Karp, 2015, Haematologica.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

H. Kantarjian, J. Cortes, C. Chuah, 2012, Blood.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Kaori Ito, A. Mead, Jennifer A. Smith, 2020, Blood advances.

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.

M. Baccarani, H. Kantarjian, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Jennifer A. Smith, G. Acton, H. Kantarjian, 2014 .

Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation

J. Cortes, H. Khoury, F. Nicolini, 2008 .

A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib

H. Kantarjian, J. Cortes, S. O'brien, 2007 .

A phase I study of INNO-406, a dual inhibitor of Abl/Lyn kinases, in adult patients with imatinib-resistant or intolerant Philadelphia chromosome positive (Ph+) leukemias

H. Kantarjian, J. Cortes, S. O'brien, 2007 .

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

H. Kantarjian, J. Cortes, J. Lipton, 2013, American journal of hematology.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T 315 I mutation

H. Kantarjian, J. Cortes, C. Chuah, 2012 .

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

M. Baccarani, J. Cortes, H. Khoury, 2015, Leukemia & lymphoma.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

H. Kantarjian, J. Lipton, H. Khoury, 2009 .

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

H. Kantarjian, J. Lipton, A. Hochhaus, 2009 .

Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.

H. Kantarjian, J. Cortes, H. Khoury, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

K. Döhner, S. Verstovsek, C. Harrison, 2021, Blood.

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

S. Verstovsek, R. Mesa, M. Talpaz, 2021, Haematologica.

Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19

J. Mascarenhas, David Park, S. Benzaquen, 2022, JAMA network open.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

T. Holyoake, E. Allan, A. Craig, 2011, Leukemia.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Arnaud Pigneux, Gary Acton, Michael Heuser, 2015, The Lancet. Oncology.

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

M. Baccarani, H. Kantarjian, J. Cortes, 2013, Haematologica.

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Population Pharmacokinetics of Clofarabine, a Second‐Generation Nucleoside Analog, in Pediatric Patients With Acute Leukemia

P. Bonate, W. Plunkett, V. Gandhi, 2004, Journal of clinical pharmacology.

Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia

A. Levine, D. Douer, K. Watkins, 2003, Leukemia & lymphoma.

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Jennifer A. Smith, H. Kantarjian, J. Cortes, 2016 .

Abstract C198: PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and tumor regression in hematologic cancer models in addition to solid tumors

S. Hansen, G. Jamieson, M. Binnerts, 2015 .

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Haematologica.

A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors.

A. Nagler, H. Kantarjian, J. Cortes, 2007 .

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

M. Baccarani, H. Kantarjian, J. Cortes, 2012 .

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

M. Baccarani, H. Kantarjian, J. Cortes, 2011 .

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

H. Kantarjian, J. Cortes, J. Lipton, 2008 .

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

S. Verstovsek, R. Mesa, A. Vannucchi, 2021, Blood.

Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Jennifer A. Smith, G. Acton, H. Kantarjian, 2015 .

VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia

Michael Craig, Robert K. Stuart, Gary Acton, 2012 .

Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors

G. Shapiro, A. Berkenblit, D. Ryan, 2005 .

Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).

M. Baccarani, H. Kantarjian, J. Cortes, 2012 .

Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation

T. Bohnert, S. Hansen, G. Jamieson, 2015 .